What drove ROG.SW stock pre-market movement today?

Pre-market moves were driven by a positive Phase II readout for petrelintida and above-average volume. Traders are weighing clinical progress against valuation, which pushed the price to CHF351.50, down 2.03% from the prior close.

How does Roche's valuation compare with its healthcare peers?

Roche trades at a trailing PE of 21.91 versus the Swiss healthcare peer average PE of 34.64. That lower PE suggests relative value, balanced against a high price-to-book of 8.28 and sector-specific risks.

What are Meyka AI's key forecasts for ROG.SW stock?

Meyka AI's model projects a monthly price of CHF348.23 and a yearly projection of CHF251.97. The monthly forecast implies near-term roughly -0.94% versus current price; forecasts are model-based and not guarantees.

Which technical levels should traders watch for ROG.SW stock?

Traders should watch a break above the Bollinger middle band near CHF362.32 for bullish confirmation and a close below the lower band at CHF349.00 for downside risk. RSI at 43.26 shows subdued momentum.

CH Stocks

CHF351.50 ROG.SW Roche Holding AG (SIX) pre-market Mar 2026: Phase II upside

ByDanny Kontos March 6, 2026March 6, 2026

ROG.SW stock opened pre-market at CHF351.50, down 2.03% on higher volume as traders react to a positive Phase II readout for petrelintida. The move left the share price below the day’s open CHF357.10 and above the intraday low CHF350.50, with volume at 1,081,253 shares. Investors on the SIX in Switzerland are weighing clinical progress against near-term valuation and sector comparisons as market activity makes Roche one of the most active names this session.